Bristol Myers Squibb Company $BMY Position Increased by denkapparat Operations GmbH

denkapparat Operations GmbH raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 46.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,358 shares of the biopharmaceutical company’s stock after buying an additional 11,154 shares during the period. Bristol Myers Squibb comprises about 1.0% of denkapparat Operations GmbH’s holdings, making the stock its 6th largest holding. denkapparat Operations GmbH’s holdings in Bristol Myers Squibb were worth $1,595,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. M&G PLC lifted its stake in Bristol Myers Squibb by 1.4% during the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after acquiring an additional 97,063 shares in the last quarter. Vanguard Group Inc. increased its stake in Bristol Myers Squibb by 0.5% during the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after purchasing an additional 1,058,803 shares during the period. Bell & Brown Wealth Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 0.5% in the third quarter. Bell & Brown Wealth Advisors LLC now owns 42,691 shares of the biopharmaceutical company’s stock valued at $1,925,000 after purchasing an additional 224 shares during the period. Tobam boosted its stake in shares of Bristol Myers Squibb by 17.3% in the third quarter. Tobam now owns 95,595 shares of the biopharmaceutical company’s stock valued at $4,311,000 after purchasing an additional 14,107 shares during the period. Finally, Pallas Capital Advisors LLC increased its stake in Bristol Myers Squibb by 44.4% during the 3rd quarter. Pallas Capital Advisors LLC now owns 32,407 shares of the biopharmaceutical company’s stock worth $1,462,000 after buying an additional 9,972 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HSBC reissued a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Guggenheim reissued a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $46.00 to $65.00 in a research report on Wednesday, January 7th. Citigroup boosted their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Eight investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $59.20.

Bristol Myers Squibb Price Performance

BMY stock opened at $60.64 on Monday. The stock has a market cap of $123.49 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The business has a 50 day moving average price of $55.33 and a 200 day moving average price of $49.48.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 EPS. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.